Abstracts members to follow up with their physicians; patient reminder postcards; educational materials and newsletters; Diabetic Control Network-a 12-month patient self educated program; vision provider contract requirement included performance guarantees to improve eye exam rates; mailings to providers a list of their diabetic patients who had not received the necessary services; provider and patient gift certificate incentive programs; providers on site education, and updated ADA diabetes standards of care. Results of baseline measurement and 12-month post intervention re-measurement were compared. RESULTS: A significant improvement in all selected quality indicators were found: HbA1c poorly controlled rate was 48.42%, a decreased of 19.46% (p < 0.001) from baseline; eye exam rates was 48.66%, an increased of 10.70% (p < 0.05) from baseline; LDL-C level <130 mg/dL was 55.96%, an increased of 10.46% (p < 0.05) from baseline, LDL-C level <100 mg/dL was 31.87%; and nephropathy monitoring was 53.28%, an increased of 8.51% (p < 0.05) from baseline. The high prevalence of undiagnosed diabetes and the large proportion of individuals with complications at diagnosis (50% according to UKPDS 33) argue for screening for Type-2 diabetes. The NHANES study confirms the substantially higher risk of death, lower survival, and lower life expectancy of diabetic adults compared with non-diabetic adults. A UK Prospective Diabetes Study shows that intensive blood-glucose control can reduce risk of any diabetes-related death and any diabetesrelated endpoints. OBJECTIVE: The aim of the study was to assess cost-effectiveness of active screening for DM and intensive blood-glucose control in comparison with conventional treatment in patients with DM II in the Polish population. METHODS: The Markov model of DM progression to stimulate lifetime and related health care cost was constructed. Demographic characteristics of a stimulated cohort as well as cost of health care were based on a CODIP study population. Costs were analysed from a societal viewpoint and included only direct medical costs. Costs of active searching for DM and the distribution of people on diagnostic pathways came from an epidemiological Screen-Pol 2 study. The age-dependant risk of death and transition probabilities between disease stages were obtained from the NHANES study. The effectiveness of active bloodglucose control was derived from the UKPDS 33. RESULTS: In the long term (20 years), a strategy based on active blood-glucose control could bring an additional 0.4 life years saved (LYS) per patient. An additional LYS costs €457. If active blood-glucose control is preceded by the active screening for DM, this strategy could bring 0.71 LYS per patient. The cost-effectiveness ratio amounts to €10,863/LYS. CONCLUSIONS: The most effective strategy in DM management is based on an early detection program and active blood-glucose control. The cost-effectiveness ratio for active glucose control is extremely low. 
PDB43 SHOULD WE LOOK FOR A NEW APPROACH IN DIABETES MELLITUS (DM) MANAGEMENT? IS IT A COST-EFFECTIVE STRATEGY IN THE POLISH SETTING?
Sieradzki The high prevalence of undiagnosed diabetes and the large proportion of individuals with complications at diagnosis (50% according to UKPDS 33) argue for screening for Type-2 diabetes. The NHANES study confirms the substantially higher risk of death, lower survival, and lower life expectancy of diabetic adults compared with non-diabetic adults. A UK Prospective Diabetes Study shows that intensive blood-glucose control can reduce risk of any diabetes-related death and any diabetesrelated endpoints. OBJECTIVE: The aim of the study was to assess cost-effectiveness of active screening for DM and intensive blood-glucose control in comparison with conventional treatment in patients with DM II in the Polish population.
METHODS:
The Markov model of DM progression to stimulate lifetime and related health care cost was constructed. Demographic characteristics of a stimulated cohort as well as cost of health care were based on a CODIP study population. Costs were analysed from a societal viewpoint and included only direct medical costs. Costs of active searching for DM and the distribution of people on diagnostic pathways came from an epidemiological Screen-Pol 2 study. The age-dependant risk of death and transition probabilities between disease stages were obtained from the NHANES study. The effectiveness of active bloodglucose control was derived from the UKPDS 33. RESULTS: In the long term (20 years), a strategy based on active blood-glucose control could bring an additional 0.4 life years saved (LYS) per patient. An additional LYS costs €457. If active blood-glucose control is preceded by the active screening for DM, this strategy could bring 0.71 LYS per patient. The cost-effectiveness ratio amounts to €10,863/LYS. CONCLUSIONS: The most effective strategy in DM management is based on an early detection program and active blood-glucose control. The cost-effectiveness ratio for active glucose control is extremely low. 
PDB44 USE OF ACETYL-SALICYLIC ACID FOR CARDIOVASCULAR PREVENTION IN PRIMARY CARE PATIENTS WITH DIABETES MELLITUS

Sicras
PDB45 PREDICTORS OF DIABETES MEDICATION UTILIZATION AND HEALTH CARE COSTS IN U.S. PATIENTS WITH TYPE-2 DIABETES: RESULTS FROM A NATIONAL SURVEY STUDY
Shenolikar R, Balkrishnan R Ohio State University College of Pharmacy, Columbus, OH, USA OBJECTIVE: This study determined the predictors of antidiabetes medication adherence and health care costs in adults with Type-2 diabetes mellitus in the United States. METHODS: The 2000 Medical Expenditure Panel survey was used for the analyses. The population for analyses was identified using ICD-9 CM codes for Type-2 diabetes. The predictor variables were demographics variables, self-reported health status (EuroQol score), and health services utilization variables. The dependent variables in this analysis were diabetes medication possession (number of diabetes medication refills) and annual health care costs. Multivariate weighted analysis was performed to identify significant predictors of medication utilization and health care costs. RESULTS: There were 11.7 million patients with reported Type-2 diabetes in the United States in 2000, based on survey extrapolation. On an average, there were ten diabetes drug refills reported by patients. The average annual health care costs for these patients were $7466, while the mean EuroQol summary score was 48%. Increase in the health status summary score (EuroQol) by 10% was associated with a slight (1%) decrease in diabetes drug refills (p < 0.05). An additional diabetes related emergency visit or an inpatient visit was associated with a nearly 50% increase compared to the average diabetes medication uti-
